U.S. Markets closed

Today's Research Reports on TSO3, Emerald Health Therapeutics, DiaMedica Therapeutics and Nuvo Pharmaceuticals

NEW YORK, NY / ACCESSWIRE / January 4, 2019 / The Market Edge strives to provide investors with free daily equity research reports analyzing major market events. Take a few minutes to register with us free at http://marketedgereport.com and get exclusive access to our numerous research reports and market updates.

The Market Edge Initiates Coverage on:

TSO3 Inc.
https://marketedgereport.com/report/TOS.TO/

Emerald Health Therapeutics, Inc.
https://marketedgereport.com/report/EMH.V/

DiaMedica Therapeutics Inc.
https://marketedgereport.com/report/DMA.V/

Nuvo Pharmaceuticals Inc.
https://marketedgereport.com/report/NRI.TO/

TSO3's stock jumped 5.56% Thursday, to close the day at $0.38. The stock recorded a trading volume of 90,500 shares, which was below its three months average volume of 131,711 shares. In the last year, TSO3's shares have traded in a range of 0.35 - 2.83. The share price has gained 8.57% from its 52 week low. The company's shares are currently trading below their 200-day moving average. The stock's 50-day moving average of $0.44 is lower than its 200-day moving average of $0.63. Shares of TSO3 have fallen approximately 85.16 percent in the last one year.

Access The Market Edge's TSO3 Inc. Research Report:
https://marketedgereport.com/report/TOS.TO/

On Thursday, shares of Emerald Health Therapeutics recorded a trading volume of 567,068 shares, which was below the three months average volume of 772,009 shares. The stock ended the day 2.58% lower at $3.02. The share price has fallen 68.8% from its 52 week high with a 52 week trading range of 2.04 - 9.68. The company's shares are currently trading below their 200-day moving average. The stock's 50-day moving average of $3.03 is lower than its 200-day moving average of $3.74. Shares of Emerald Health Therapeutics have fallen approximately 62.30 percent in the last one year.

Access The Market Edge's Emerald Health Therapeutics, Inc. Research Report:
https://marketedgereport.com/report/EMH.V/

DiaMedica Therapeutics' stock jumped 8.6% Thursday, to close the day at $4.67. The stock recorded a trading volume of 11,831 shares, which was below its three months average volume of 72,140 shares. In the last year, DiaMedica Therapeutics' shares have traded in a range of 3.33 - 18.00. The share price has gained 40.24% from its 52 week low. The company's shares are currently trading below their 200-day moving average. The stock's 50-day moving average of $5.31 is lower than its 200-day moving average of $9.92. Shares of DiaMedica Therapeutics have fallen approximately 24.68 percent in the last one year.

Access The Market Edge's DiaMedica Therapeutics Inc. Research Report:
https://marketedgereport.com/report/DMA.V/

On Thursday, shares of Nuvo Pharmaceuticals recorded a trading volume of 729 shares, which was below the three months average volume of 5,037 shares. The stock ended the day 1.29% higher at $2.36. The share price has fallen 42.86% from its 52 week high with a 52 week trading range of 1.85 - 4.13. The company's shares are currently trading below their 200-day moving average. The stock's 50-day moving average of $2.43 is lower than its 200-day moving average of $2.70. Shares of Nuvo Pharmaceuticals have fallen approximately 39.49 percent in the last one year.

Access The Market Edge's Nuvo Pharmaceuticals Inc. Research Report:
https://marketedgereport.com/report/NRI.TO/

Our Actionable Research on TSO3 Inc. (TSX : TOS.TO ), Emerald Health Therapeutics, Inc. (TSXV : EMH.V ), DiaMedica Therapeutics Inc. (TSXV : DMA.V ) and Nuvo Pharmaceuticals Inc. (TSX : NRI.TO ) can be downloaded free of charge at The Market Edge.

The Market Edge

We are committed to providing relevant and actionable information for the self-directed investor. Our research is reputed for being a leader in trusted, in-depth analysis vital for informed strategic trading decisions. The nimble investor can leverage our analysis and collective expertise to execute a disciplined approach to stock selection.

The Market Edge has not been compensated; directly or indirectly; for producing or publishing this document.

Disclaimer: This article is written by an independent contributor of MarketEdgeReport.com and Nadia Noorani, a CFA® charter holder, has provided necessary guidance in preparing the document templates. MarketEdgeReport.com is neither a registered broker dealer nor a registered investment advisor. For more information please read our full disclaimer at www.marketedgereport.com/disclaimer.

CONTACT

For any questions, inquiries, or comments reach out to us directly at:

Address:

The Market Edge, Unit #901 511 Avenue of the Americas, New York, NY, 10011

Email:

contact@marketedgereport.com

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: The Market Edge